They injected human serum albumin nanoparticles containing the photothermal agent IR780 (HIR780), ribonuclease A (RNase A), poloxamer 407 and α-cyclodextrin (the primary material for hydrogel formation) into the tumor for in situ gelling (in situ gelling is the administration of a drug in a solution form with an immediate phase transition at the site of administration from a liquid state to a non-chemically cross-linked semi-solid formulation of the gel). Here, RNASE1 is linked to neoplasm.